Literature DB >> 2938613

Does 2-mercaptoethane sulphonate (mesna) prevent cyclophosphamide and azathioprine induced immunosuppression? In vitro studies.

S A Al-Safi, J L Maddocks.   

Abstract

The effect of 2-mercaptoethane sulphonate (mesna) on the inhibition of the human MLR by 4-hydroxycyclophosphamide or azathioprine was studied. 4-Hydroxycyclophosphamide (34 microM) completely inhibited the MLR and this inhibition was unaffected by 122 microM of 2-mercaptoethane sulphonate or its disulphide. At high concentrations (mM) 2-mercaptoethane sulphonate inhibited the MLR reaching 85% at 24 mM. 2-Mercaptoethane sulphonate (15-122 microM) had no effect on azathioprine (36 microM) inhibition. The results of these in vitro studies suggest that 2-mercaptoethane sulphonate does not interfere with cyclophosphamide or azathioprine induced suppression of cellular immunity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938613      PMCID: PMC1400868          DOI: 10.1111/j.1365-2125.1986.tb05189.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine.

Authors:  A Watanabe; N Hobara; H Nagashima
Journal:  Acta Med Okayama       Date:  1978-07       Impact factor: 0.892

2.  The incidence of bladder cancer after cyclophosphamide therapy.

Authors:  W V Fairchild; C R Spence; H D Solomon; M P Gangai
Journal:  J Urol       Date:  1979-08       Impact factor: 7.450

3.  Combined prednisolone, azathioprine, and cyclophosphamide treatment for persistent proliferative glomerulonephritis in adults.

Authors:  A P Mukherjee
Journal:  Lancet       Date:  1971-12-18       Impact factor: 79.321

4.  Mesna versus forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplant patients (preliminary data).

Authors:  J Hows; A Mehta; E C Gordon-Smith
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

5.  The development of mesna for regional detoxification.

Authors:  N Brock; J Pohl
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

6.  Cancer in patients treated with immunosuppressive drugs.

Authors:  L J Kinlen; J Peto; R Doll; A G Sheil
Journal:  Br Med J (Clin Res Ed)       Date:  1981-02-07

7.  Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.

Authors:  N Brock; J Stekar; J Pohl; U Niemeyer; G Scheffler
Journal:  Arzneimittelforschung       Date:  1979

8.  Azathioprine and 6-mercaptopurine (6-MP) suppress the human mixed lymphocyte reaction (MLR) by different mechanisms.

Authors:  S A Al-Safi; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

9.  Clinical overview of mesna.

Authors:  H Burkert
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

10.  Does cyclophosphamide induce bladder cancer?

Authors:  R M Pearson; M S Soloway
Journal:  Urology       Date:  1978-05       Impact factor: 2.649

View more
  1 in total

1.  In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas.

Authors:  A H Jäger; U Bogdahn; R Apfel; B Pfeufer; A Dekant
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.